Top

Current Pain and Headache Reports

Published in:

01-05-2022 | Migraine | Chronic Daily Headache (SJ Wang and SP Chen, Section Editors)

Sex Differences in Chronic Migraine: Focusing on Clinical Features, Pathophysiology, and Treatments

Authors: Chia-Kuang Tsai, Chia-Lin Tsai, Guan-Yu Lin, Fu-Chi Yang, Shuu-Jiun Wang

Published in: Current Pain and Headache Reports | Issue 5/2022

Abstract

Purpose of Review

This review provides an update on sex differences in chronic migraine (CM), with a focus on clinical characteristics, pathophysiology, and treatments.

Recent Findings

Approximately 6.8–7.8% of all migraineurs have CM, with an estimated prevalence of 1.4–2.2% in the general population. The economic burden caused by CM, including medical costs and lost working ability, is threefold higher than that caused by episodic migraine (EM). Notably, the prevalence of migraine is affected by age and sex. Female migraineurs with CM experience higher levels of headache-related disability, including longer headache duration, higher frequency of attacks, and more severely impacted efficiency at work. Sex hormones, including estrogen, testosterone, and progesterone, contribute to the sexually dimorphic characteristics and prevalence of migraine in men and women. Recent neuroimaging studies have indicated that migraine may have a greater impact and cause greater dysfunction in the organization of resting-state functional networks in women. Accumulating evidence suggests that topiramate, Onabotulinumtoxin A and calcitonin gene-related peptide (CGRP) monoclonal antibodies are effective as the preventative treatments for CM.

Summary

Recent evidence highlights a divergence in the characteristics of CM between male and female populations. The data comparing the treatment response for CM regarding sex are lacking.

Headache Classification Committee of the International Headache S. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808. https://doi.org/10.1177/0333102413485658.

Wang SJ, Wang PJ, Fuh JL, Peng KP, Ng K. Comparisons of disability, quality of life, and resource use between chronic and episodic migraineurs: a clinic-based study in Taiwan. Cephalalgia. 2013;33:171–81. https://doi.org/10.1177/0333102412468668.CrossRefPubMed

Tang CH, Chen YC, Ng K, Wang SJ. A retrospective matched case-control study on medical costs of refractory migraine in Taiwan. Headache. 2013;53:526–39. https://doi.org/10.1111/head.12039.CrossRefPubMed

Lewis DW. Pediatric migraine. Pediatr Rev. 2007;28:43–53. https://doi.org/10.1542/pir.28-2-43.CrossRefPubMed

Macgregor EA, Rosenberg JD, Kurth T. Sex-related differences in epidemiological and clinic-based headache studies. Headache. 2011;51:843–59. https://doi.org/10.1111/j.1526-4610.2011.01904.x.CrossRefPubMed

• Tonini MC. Gender differences in migraine. Neurol Sci. 2018;39:77-8. https://doi.org/10.1007/s10072-018-3378-2. Detail review of sex hormone related neuromediators and neurotransmitters involved in migraine pathogenesis.

Stewart WF, Wood C, Reed ML, Roy J, Lipton RB, Group AA. Cumulative lifetime migraine incidence in women and men. Cephalalgia. 2008;28:1170–8. https://doi.org/10.1111/j.1468-2982.2008.01666.x.CrossRef

Manzoni GC, P T. Epidemiology of migraine. J Headache Pain. 2003;4:S18-S22. https://doi.org/10.1007/s101940300003.

Russell MB, Rasmussen BK, Thorvaldsen P, Olesen J. Prevalence and sex-ratio of the subtypes of migraine. Int J Epidemiol. 1995;24:612–8. https://doi.org/10.1093/ije/24.3.612.CrossRefPubMed

10.

•• Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML. A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability. Headache. 2016;56:1280-9. https://doi.org/10.1111/head.12878. Both CaMEO and AMPP are longitudinal studies recruiting a large CM population designed to evaluate the features of headache and headache-associated disability. These two studies reorted similar conclusion that migraineurs with CM had more disability than EM.

11.

Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30:599–609. https://doi.org/10.1111/j.1468-2982.2009.01941.x.CrossRefPubMed

12.

Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, Lipton RB. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52:1456–70. https://doi.org/10.1111/j.1526-4610.2012.02223.x.CrossRefPubMed

13.

Katsarava Z, Dzagnidze A, Kukava M, Mirvelashvili E, Djibuti M, Janelidze M, Jensen R, Stovner LJ, Steiner TJ, Lifting The Burden: The Global Campaign to Reduce the Burden of Headache W, the Russian Linguistic Subcommittee of the International Headache S. Primary headache disorders in the Republic of Georgia: prevalence and risk factors. Neurology. 2009;73:1796–803. https://doi.org/10.1212/WNL.0b013e3181c34abb.

14.

da Silva A, Jr., Costa EC, Gomes JB, Leite FM, Gomez RS, Vasconcelos LP, Krymchantowski A, Moreira P, Teixeira AL. Chronic headache and comorbidities: a two-phase, population-based, cross-sectional study. Headache. 2010; 50: 1306-12. doi: https://doi.org/10.1111/j.1526-4610.2010.01620.x.

15.

Tsai CK, Liang CS, Lin GY, Tsai CL, Lee JT, Sung YF, Lin YK, Hung KS, Chen WL, Yang FC. Identifying genetic variants for age of migraine onset in a Han Chinese population in Taiwan. J Headache Pain. 2021;22:89. https://doi.org/10.1186/s10194-021-01301-y.CrossRefPubMedPubMedCentral

16.

Cologno D, De Pascale A, Manzoni GC. Familial occurrence of migraine with aura in a population-based study. Headache. 2003;43:231–4. https://doi.org/10.1046/j.1526-4610.2003.03046.x.CrossRefPubMed

17.

Russell MB, Hilden J, Sorensen SA, Olesen J. Familial occurrence of migraine without aura and migraine with aura. Neurology. 1993;43:1369–73. https://doi.org/10.1212/wnl.43.7.1369.CrossRefPubMed

18.

Hsu YW, Liang CS, Lee JT, Chu HT, Lee MS, Tsai CL, Lin GY, Lin YK, Ho TH, Yang FC. Associations between migraine occurrence and the effect of aura, age at onset, family history, and sex: A cross-sectional study. PLoS ONE. 2020;15: e0228284. https://doi.org/10.1371/journal.pone.0228284.CrossRefPubMedPubMedCentral

19.

Chambers CT, Craig KD, Bennett SM. The impact of maternal behavior on children’s pain experiences: an experimental analysis. J Pediatr Psychol. 2002;27:293–301. https://doi.org/10.1093/jpepsy/27.3.293.CrossRefPubMed

20.

Stark RJ, Ravishankar K, Siow HC, Lee KS, Pepperle R, Wang SJ. Chronic migraine and chronic daily headache in the Asia-Pacific region: a systematic review. Cephalalgia. 2013;33:266–83. https://doi.org/10.1177/0333102412468677.CrossRefPubMed

21.

Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache. 1998;38:497–506. https://doi.org/10.1046/j.1526-4610.1998.3807497.x.CrossRefPubMed

22.

Messali A, Sanderson JC, Blumenfeld AM, Goadsby PJ, Buse DC, Varon SF, Stokes M, Lipton RB. Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey. Headache. 2016;56:306–22. https://doi.org/10.1111/head.12755.CrossRefPubMed

23.

Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB. Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med. 2010;52:8–14. https://doi.org/10.1097/JOM.0b013e3181c1dc56.CrossRefPubMed

24.

Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159:813–8. https://doi.org/10.1001/archinte.159.8.813.CrossRefPubMed

25.

Fuh J-L, Wang S-J, Lu S-R. Impact of migraine on the employed labor force in Taiwan. J Chin Med Assoc. 2008;71:74–8. https://doi.org/10.1016/s1726-4901(08)70078-9.CrossRefPubMed

26.

Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lanteri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barre J, Andree C. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain. 2014;15:31. https://doi.org/10.1186/1129-2377-15-31.

27.

Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81:428–32. https://doi.org/10.1136/jnnp.2009.192492.CrossRefPubMed

28.

Chen YC, Tang CH, Ng K, Wang SJ. Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan. J Headache Pain. 2012;13:311–9. https://doi.org/10.1007/s10194-012-0447-4.CrossRefPubMedPubMedCentral

29.

Delaruelle Z, Ivanova TA, Khan S, Negro A, Ornello R, Raffaelli B, Terrin A, Mitsikostas DD, Reuter U, European Headache Federation School of Advanced S. Male and female sex hormones in primary headaches. J Headache Pain. 2018;19:117. https://doi.org/10.1186/s10194-018-0922-7.

30.

Allais G, Chiarle G, Sinigaglia S, Benedetto C. Menstrual migraine: a review of current and developing pharmacotherapies for women. Expert Opin Pharmacother. 2018;19:123–36. https://doi.org/10.1080/14656566.2017.1414182.CrossRefPubMed

31.

Calhoun AH, Batur P. Combined hormonal contraceptives and migraine: an update on the evidence. Cleve Clin J Med. 2017;84:631–8. https://doi.org/10.3949/ccjm.84a.16033.CrossRefPubMed

32.

Pavlovic JM, Allshouse AA, Santoro NF, Crawford SL, Thurston RC, Neal-Perry GS, Lipton RB, Derby CA. Sex hormones in women with and without migraine: Evidence of migraine-specific hormone profiles. Neurology. 2016;87:49–56. https://doi.org/10.1212/WNL.0000000000002798.CrossRefPubMedPubMedCentral

33.

Taha MA, Mohammed EA. Assessment of Hormonal Changes in Female Patients with Migraine. Indian J Public Health Res Dev. 2019;10. https://doi.org/10.5958/0976-5506.2019.01335.4.

34.

Palmirotta R, Barbanti P, Ialongo C, De Marchis ML, Alessandroni J, Egeo G, Aurilia C, Fofi L, Valente MG, Ferroni P, Della-Morte D, Guadagni F. Progesterone receptor gene (PROGINS) polymorphism correlates with late onset of migraine. DNA Cell Biol. 2015;34:208–12. https://doi.org/10.1089/dna.2014.2534.CrossRefPubMedPubMedCentral

35.

Shields LBE, Seifert T, Shelton BJ, Plato BM. Testosterone levels in men with chronic migraine. Neurol Int. 2019;11:8079. https://doi.org/10.4081/ni.2019.8079.CrossRefPubMedPubMedCentral

36.

Li W, Diao X, Chen C, Li C, Zhang Y, Li Y. Changes in hormones of the hypothalamic-pituitary-gonadal axis in migraine patients. J Clin Neurosci. 2018;50:165–71. https://doi.org/10.1016/j.jocn.2017.11.011.CrossRefPubMed

37.

•• Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017;16:76-87. https://doi.org/10.1016/s1474-4422(16)30293-9. An important and recent review of sex differences in the epidemiology, clinical features, and pathophysiology of migraine.

38.

Maleki N, Barmettler G, Moulton EA, Scrivani S, Veggeberg R, Spierings ELH, Burstein R, Becerra L, Borsook D. Female migraineurs show lack of insular thinning with age. Pain. 2015;156:1232–9. https://doi.org/10.1097/j.pain.0000000000000159.CrossRefPubMedPubMedCentral

39.

Dai Z, Zhong J, Xiao P, Zhu Y, Chen F, Pan P, Shi H. Gray matter correlates of migraine and gender effect: a meta-analysis of voxel-based morphometry studies. Neuroscience. 2015;299:88–96. https://doi.org/10.1016/j.neuroscience.2015.04.066.CrossRefPubMed

40.

Kruit MC, van Buchem MA, Launer LJ, Terwindt GM, Ferrari MD. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia. 2010;30:129–36. https://doi.org/10.1111/j.1468-2982.2009.01904.x.CrossRefPubMedPubMedCentral

41.

Liu J, Qin W, Nan J, Li J, Yuan K, Zhao L, Zeng F, Sun J, Yu D, Dong M, Liu P, von Deneen KM, Gong Q, Liang F, Tian J. Gender-related differences in the dysfunctional resting networks of migraine suffers. PLoS ONE. 2011;6: e27049. https://doi.org/10.1371/journal.pone.0027049.CrossRefPubMedPubMedCentral

42.

Zhang J, Su J, Wang M, Zhao Y, Zhang QT, Yao Q, Lu H, Zhang H, Li GF, Wu YL, Liu YS, Liu FD, Zhuang MT, et al. The posterior insula shows disrupted brain functional connectivity in female migraineurs without aura based on Brainnetome Atlas. Sci Rep. 2017;7:16868. https://doi.org/10.1038/s41598-017-17069-8.CrossRefPubMedPubMedCentral

43.

Androulakis XM, Krebs K, Peterlin BL, Zhang T, Maleki N, Sen S, Rorden C, Herath P. Modulation of intrinsic resting-state fMRI networks in women with chronic migraine. Neurology. 2017;89:163–9. https://doi.org/10.1212/WNL.0000000000004089.CrossRefPubMedPubMedCentral

44.

Liu J, Qin W, Nan J, Li J, Yuan K, Zhao L, Zeng F, Sun J, Yu D, Dong M, Liu P, von Deneen KM, Gong Q, et al. Gender-related differences in the dysfunctional resting networks of migraine suffers. PLoS ONE. 2011;6: e27049. https://doi.org/10.1371/journal.pone.0027049.CrossRefPubMedPubMedCentral

45.

Al-Hassany L, Haas J, Piccininni M, Kurth T, Maassen Van Den Brink A, Rohmann JL. Giving researchers a headache - sex and gender differences in migraine. Front Neurol. 2020;11:549038. https://doi.org/10.3389/fneur.2020.549038.

46.

Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(Suppl 2):47–55. https://doi.org/10.1111/head.13081.CrossRefPubMed

47.

Goadsby PJ, Lipton RB, Ferrari MD. Migraine–current understanding and treatment. N Engl J Med. 2002;346:257–70. https://doi.org/10.1056/NEJMra010917.CrossRefPubMed

48.

Valdemarsson S, Edvinsson L, Hedner P, Ekman R. Hormonal influence on calcitonin gene-related peptide in man: effects of sex difference and contraceptive pills. Scand J Clin Lab Invest. 1990;50:385–8. https://doi.org/10.3109/00365519009091595.CrossRefPubMed

49.

Stevenson JC, Macdonald DW, Warren RC, Booker MW, Whitehead MI. Increased concentration of circulating calcitonin gene related peptide during normal human pregnancy. Br Med J (Clin Res Ed). 1986;293:1329–30. https://doi.org/10.1136/bmj.293.6558.1329.CrossRef

50.

•• Ibrahimi K, van Oosterhout WP, van Dorp W, Danser AH, Garrelds IM, Kushner SA, Lesaffre EM, Terwindt GM, Ferrari MD, van den Meiracker AH, MaassenVanDenBrink A. Reduced trigeminovascular cyclicity in patients with menstrually related migraine. Neurology. 2015;84:125-31. https://doi.org/10.1212/WNL.0000000000001142. An important study provides evidence for a reduced menstrual cyclicity of both estradiol levels and the trigeminovascular vasodilator system in patients with menstrually related migraine.

51.

Ibrahimi K, Vermeersch S, Frederiks P, Geldhof V, Draulans C, Buntinx L, Lesaffre E, MaassenVanDenBrink A, de Hoon J. The influence of migraine and female hormones on capsaicin-induced dermal blood flow. Cephalalgia. 2017;37:1164–72. https://doi.org/10.1177/0333102416668659.CrossRefPubMed

52.

MaassenVanDenBrink A, Meijer J, Villalon CM, Ferrari MD. Wiping Out CGRP: Potential Cardiovascular Risks. Trends Pharmacol Sci. 2016;37:779–88. https://doi.org/10.1016/j.tips.2016.06.002.CrossRefPubMed

53.

Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltran E, Vigneri S, Edvinsson L, Maassen Van Den Brink A, European Headache Federation School of Advanced S. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017;18:96. https://doi.org/10.1186/s10194-017-0807-1.

54.

Buse DC, Loder EW, Gorman JA, Stewart WF, Reed ML, Fanning KM, Serrano D, Lipton RB. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53:1278–99. https://doi.org/10.1111/head.12150.CrossRefPubMed

55.

Brusa P, Allais G, Rolando S, Baratta F, Giaccone M, Bussone G, Allais R, Benedetto C. Migraine attacks in the pharmacy: a gender subanalysis on treatment preferences. Neurol Sci. 2015;36(Suppl 1):93–5. https://doi.org/10.1007/s10072-015-2156-7.CrossRefPubMed

56.

Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55(Suppl 2):103–22;quiz 23–6. https://doi.org/10.1111/head.12505_2.

57.

Sun-Edelstein C, Rapoport AM. Update on the pharmacological treatment of chronic migraine. Curr Pain Headache Rep. 2016;20:6. https://doi.org/10.1007/s11916-015-0533-9.CrossRefPubMed

58.

Weatherall MW. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis. 2015;6:115–23. https://doi.org/10.1177/2040622315579627.CrossRefPubMedPubMedCentral

59.

• Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84:688-95. https://doi.org/10.1212/WNL.0000000000001256. A study highlights the importance of acute treatment efficacy of EM.

60.

May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12:455–64. https://doi.org/10.1038/nrneurol.2016.93.CrossRefPubMed

61.

Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48:1157–68. https://doi.org/10.1111/j.1526-4610.2008.01217.x.CrossRefPubMed

62.

Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6:573–82. https://doi.org/10.1038/nrneurol.2010.127.CrossRefPubMed

63.

American HS. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1–18. https://doi.org/10.1111/head.13456.CrossRef

64.

••Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, Pozo-Rosich P, Martelletti P, Ducros A, Lanteri-Minet M, Braschinsky M, Del Rio MS, Daniel O, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021. https://doi.org/10.1038/s41582-021-00509-5. A comprehensive review outlines the effective treatment for EM and CM, including how to evaluate treatment response and handling treatment failure.

65.

Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Saper J, Ascher S, Jordan DM, Greenberg SJ, Hulihan J, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170–80. https://doi.org/10.1111/j.1526-4610.2006.00684.x.CrossRefPubMed

66.

Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, Group T-M-S. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–23. https://doi.org/10.1111/j.1468-2982.2007.01326.x.

67.

Hunt S, Russell A, Smithson WH, Parsons L, Robertson I, Waddell R, Irwin B, Morrison PJ, Morrow J, Craig J, Epilepsy UK, Pregnancy R. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology. 2008;71:272–6. https://doi.org/10.1212/01.wnl.0000318293.28278.33.CrossRefPubMed

68.

Hernandez-Diaz S, Huybrechts KF, Desai RJ, Cohen JM, Mogun H, Pennell PB, Bateman BT, Patorno E. Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study. Neurology. 2018;90:e342–51. https://doi.org/10.1212/WNL.0000000000004857.CrossRefPubMedPubMedCentral

69.

Stubberud A, Flaaen NM, McCrory DC, Pedersen SA, Linde M. Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis. Pain. 2019;160:762–72. https://doi.org/10.1097/j.pain.0000000000001456.CrossRefPubMed

70.

Lai KL, Niddam DM, Fuh JL, Chen SP, Wang YF, Chen WT, Wu JC, Wang SJ. Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial. Acta Neurol Scand. 2017;135:476–83. https://doi.org/10.1111/ane.12626.CrossRefPubMed

71.

Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, Group PCMS. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921–36. https://doi.org/10.1111/j.1526-4610.2010.01678.x.CrossRef

72.

Sacco S, Russo A, Geppetti P, Grazzi L, Negro A, Tassorelli C, Tedeschi G, Martelletti P. What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group. Expert Rev Neurother. 2020;20:1275–86. https://doi.org/10.1080/14737175.2020.1825077.CrossRefPubMed

73.

Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives N, Clarke CE, Sinclair A. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev. 2018;6:CD011616. https://doi.org/10.1002/14651858.CD011616.pub2.

74.

Patel N, Barnhart R, Konkol P, Varda J, Nelson R, Smith T. Treatment of migraine: a review of disease burden and an update on the therapeutic landscape for pharmacists. Drugs & Therapy Perspectives. 2020;37:75–86. https://doi.org/10.1007/s40267-020-00801-2.CrossRef

75.

Ornello R, Baraldi C, Guerzoni S, Lambru G, Fuccaro M, Raffaelli B, Gendolla A, Barbanti P, Aurilia C, Cevoli S, Favoni V, Vernieri F, Altamura C, Russo A, Silvestro M, Dalla Valle E, Mancioli A, Ranieri A, Alfieri G, Latysheva N, Filatova E, Talbot J, Cheng S, Holle D, Scheffler A, Nežádal T, Čtrnáctá D, Šípková J, Matoušová Z, Sette L, Casalena A, Maddestra M, Viola S, Affaitati G, Giamberardino MA, Pistoia F, Reuter U, Sacco S. Gender differences in 3-month outcomes of erenumab treatment-study on efficacy and safety of treatment with erenumab in men. Front Neurol. 2021;12: 774341. https://doi.org/10.3389/fneur.2021.774341.CrossRefPubMedPubMedCentral

76.

Hulla R, Liegey-Dougall A. A systematic review of high-frequency transcranial magnetic stimulation on motor cortex areas as a migraine preventive treatment. Cephalalgia Reports. 2019;2. https://doi.org/10.1177/2515816319889971.

77.

Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, Gerard P, Magis D. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013;80:697–704. https://doi.org/10.1212/WNL.0b013e3182825055.CrossRefPubMed

78.

Di Fiore P, Bussone G, Galli A, Didier H, Peccarisi C, D’Amico D, Frediani F. Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial. Neurol Sci. 2017;38:201–6. https://doi.org/10.1007/s10072-017-2916-7.CrossRefPubMed

79.

Ordas CM, Cuadrado ML, Pareja JA, de-Las-Casas-Camara G, Gomez-Vicente L, Torres-Gaona G, Venegas-Perez B, Alvarez-Marino B, Diez Barrio A, Pardo-Moreno J. Transcutaneous supraorbital stimulation as a preventive treatment for chronic migraine: a prospective, open-label study. Pain Med. 2020;21:415–22. https://doi.org/10.1093/pm/pnz119.

80.

Silberstein SD, Calhoun AH, Lipton RB, Grosberg BM, Cady RK, Dorlas S, Simmons KA, Mullin C, Liebler EJ, Goadsby PJ, Saper JR, Group ES. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. Neurology. 2016;87:529–38. https://doi.org/10.1212/WNL.0000000000002918.CrossRef

Title: Sex Differences in Chronic Migraine: Focusing on Clinical Features, Pathophysiology, and Treatments
Authors: Chia-Kuang Tsai
Chia-Lin Tsai
Guan-Yu Lin
Fu-Chi Yang
Shuu-Jiun Wang
Publication date: 01-05-2022
Publisher: Springer US
Keywords: Migraine
Aura
Headache
Topiramate
Estrogens
Progesterone
Testosterone
Published in: Current Pain and Headache Reports / Issue 5/2022
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI: https://doi.org/10.1007/s11916-022-01034-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Sex Differences in Chronic Migraine: Focusing on Clinical Features, Pathophysiology, and Treatments

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 5/2022

Postcraniotomy Headache: Etiologies and Treatments

Neuromodulation Interventions for the Treatment of Painful Diabetic Neuropathy: a Systematic Review

Review of Sacroiliac Joint Injection Techniques

Cognitive Impairment in Primary and Secondary Headache Disorders

Post-COVID Pain Syndromes